房颤患者抗凝桥接治疗:风险与获益再平衡的最新进展
本文综述近5年证据及指南共识,更新房颤患者使用维生素K拮抗剂(VKA)围术期桥接治疗的推荐。前瞻性试验及一项随机对照试验显示,肝素桥接较不桥接显著增加出血风险,且实际围术期血栓栓塞风险可能低于既往估计;但高卒中风险患者代表性不足。
要点
- 肝素桥接较不桥接显著增加出血风险。
- 实际围术期血栓栓塞风险可能低于既往估计。
- 桥接决策前应评估血栓与出血风险。
核心结论
- 肝素桥接与不桥接相比显著增加出血风险,且围术期血栓栓塞风险可能低于既往估计。
- 高卒中风险患者在试验中代表性不足,桥接决策需个体化评估血栓与出血风险。
研究设计与样本
- 文献综述,检索近5年证据及指南和共识声明。
- 纳入前瞻性试验及一项随机对照试验,评估VKA用于房颤的围术期桥接治疗。
主要发现
- 肝素桥接较不桥接显著增加出血风险。
- 数据提示实际围术期血栓栓塞风险可能低于既往估计。
- 高卒中风险患者未得到充分代表。
关键数值与推荐
- 至少4项主要国际指南已更新,并发布了一份新的桥接治疗共识文件。
- 血栓与出血风险评估工具已出现并纳入指南推荐。
临床怎么用
- 使用VKA的房颤患者围术期决策前应评估血栓和出血风险。
- 可借助血栓与出血风险评估工具辅助桥接决策。
局限性
- 高卒中风险患者代表性不足。
- 正在进行的试验结果有待公布以提供更多指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2011 we reviewed clinical updates and controversies surrounding anticoagulation bridge therapy in patients with atrial fibrillation (AF). Since then, options for oral anticoagulation have expanded with the addition of four direct oral anticoagulant (DOAC) agents available in the United States. Nonetheless, vitamin K antagonist (VKA) therapy continues to be the treatment of choice for patients who are poor candidates for a DOAC and for whom bridge therapy remains a therapeutic dilemma. This literature review identifies evidence and guideline and consensus statements from the last 5 years to provide updated recommendations and insight into bridge therapy for patients using a VKA for AF. Since our last review, at least four major international guidelines have been updated plus a new consensus document addressing bridge therapy was released. Prospective trials and one randomized controlled trial have provided guidance for perioperative bridge therapy. The clinical trial data showed that bridging with heparin is associated with a significant bleeding risk compared with not bridging; furthermore, data suggested that actual perioperative thromboembolic risk may be lower than previously estimated. Notably, patients at high risk for stroke have not been adequately represented. These findings highlight the importance of assessing thrombosis and bleeding risk before making bridging decisions. Thrombosis and bleeding risk tools have emerged to facilitate this assessment and have been incorporated into guideline recommendations. Results from ongoing trials are expected to provide more guidance on safe and effective perioperative management approaches for patients at high risk for stroke.
引用
- Garwood CL, Korkis B, Grande D, et al. Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit. Pharmacotherapy. 2017. PMID: 28475278. doi:10.1002/phar.1937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。